The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).
Michael Seckl
No relevant relationships to disclose
Christian Ottensmeier
No relevant relationships to disclose
Michael H. Cullen
No relevant relationships to disclose
Peter Schmid
No relevant relationships to disclose
Lindsay E. James
No relevant relationships to disclose
Christina Wadsworth
No relevant relationships to disclose
Hannah Farrant
No relevant relationships to disclose
Dakshinamoorthy Muthukumar
No relevant relationships to disclose
Joyce Thompson
No relevant relationships to disclose
Susan Harden
No relevant relationships to disclose
Gary William Middleton
No relevant relationships to disclose
Kate Fife
No relevant relationships to disclose
Barbara Crosse
No relevant relationships to disclose
Paul Taylor
No relevant relationships to disclose
Iftekhar Khan
No relevant relationships to disclose